In its ongoing pursuit to become the first distributor of oral insulin, Oramed is set to begin a Phase II trial of its Type 2 diabetes pill in the U.S. once a smaller study required by the FDA is complete.
EpiVax and Novozymes have joined forces, attaching an autoimmune drug to a delivery protein--and by doing so the companies hope to carve themselves a $3 billion piece out of the global autoimmune market.
Researchers at Barcelona's Vall d'Hebron Institute of Oncology in Spain and U.S. biotech Alnylam Pharmaceuticals have shown that, with a novel delivery technique, they can actively "silence" cancer genes with molecules using the selective interference technique, RNAi.
California-based Genelux helmed a first-in-man trial of its new mesothelioma treatment at Memorial Sloan-Kettering Cancer Center in New York.
Drug delivery giant Medgenics ($MEDG) is looking to collect $29.4 million in an effort to develop and commercialize its Biopump delivery platform designed to treat anemia, hepatitis and hemophilia.
The FDA signed off on Smiths Medical's "smart" infusion pump that includes error-prevention software for a variety of therapies. The company says its CADD-Solis VIP pump improves on the patient interface and minimizes the potential for device failure.
Researchers at the University of California, Los Angeles, have created what could be a new way to treat cancer, combining nanotechnology with a genetic kill switch.
Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status.
Kala Pharmaceuticals received a grant from the Cystic Fibrosis Foundation to demonstrate that the company's mucosal-barrier-penetrating nanoparticle can do the same across bacterial biofilms, a symptom of cystic fibrosis.
Rockwell Medical reported positive results in its clinical study of a system designed to more effectively deliver iron to patients during dialysis.
U.K.-based BTG International submitted a new drug application to the FDA for a microfoam injection that treats varicose veins.
Call it the Trojan horse of nanomedicine: Researchers have developed a way to cloak drug-carrying nanoparticles with the same membranes as the body's own white blood cells, allowing those drugs to bypass the immune system without being harmed.
Researchers at the Indian Institute of Technology Kharagpur have created nanoparticles out of silk fibers that can deliver drugs to specific targets when combined with other proteins.
Taiwanese drugmaker ScinoPharm will use Foresee Pharmaceuticals' controlled-release technology to produce a generic prostate cancer drug.
Getting cancer treatments straight to where they are needed is a holy grail for biotechs, and a new research program from Algeta is harnessing the power of one of Immunomedics' antibodies to try to achieve this goal.
Nanyang Technological University in Singapore has opened a new research center, the Ocular Therapeutic Engineering Centre, which will focus on drug delivery to the eye.
A dual-hormone "artificial pancreas" is better at controlling type I diabetes than a simple insulin pump, which could be good news for the two-thirds of diabetics who don't achieve their blood sugar targets with existing treatments.
Researchers in Switzerland have created a novel drug delivery system using nanosized magnets to deliver toxic drugs to specific parts of a patient's body. The triggered delivery is a step toward creating "intelligent" drugs with highly targeted functions.
A "tunable" jellylike depot could extend the half-life of peptide drugs, allowing delivery without the peaks and troughs often associated with these drugs.
The prescription Auvi-Q injection device, now available in the U.S. from Sanofi, provides step-by-step instructions for the user that include audible and visual cues and an injection countdown.